# GRN

## Overview
The GRN gene encodes the granulin precursor protein, known as progranulin (PGRN), which is a secreted glycoprotein involved in a multitude of biological processes. PGRN is categorized as a growth factor and is crucial for regulating inflammation, wound healing, and tumorigenesis. It is expressed in diverse tissues, including neurons and immune cells, where it modulates cell growth and survival. PGRN functions as a neurotrophic factor in the central nervous system, promoting neuron survival and neurite outgrowth, and is involved in key signaling pathways such as MAPK/ERK and PI3K/Akt (Toh2011Structure; Paushter2018The). The protein is processed into granulin peptides, which have distinct biological activities, often contrasting with the anti-inflammatory effects of PGRN itself (Toh2011Structure; Paushter2018The). Mutations in the GRN gene are linked to several neurodegenerative diseases, including frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis, highlighting its clinical significance (Rademakers2008Common; Terryn2021Tweaking).

## Structure
The GRN gene encodes the granulin precursor protein, progranulin (PGRN), which is a secreted glycoprotein composed of 7.5 granulin repeats. The primary structure of PGRN consists of 593 amino acids with a predicted molecular mass of 63.5 kDa (Karamysheva2019Granulin). The protein includes a signal peptide at the N-terminus for secretion, followed by highly conserved cysteine-rich tandem repeats known as granulins, separated by divergent linker sequences (Karamysheva2019Granulin). 

The secondary structure of PGRN involves a unique arrangement where the 12-cysteine granulin motif forms six disulfide bridges, resulting in a three-dimensional structure of a parallel stack of beta-hairpins in the form of a left-handed helix (Toh2011Structure). 

PGRN undergoes post-translational modifications, including glycosylation, which is crucial for protein folding, stability, and interactions. It is predicted to have five N-glycosylation sites, with specific granulins harboring one site each (Zhang2022Differential). The mature protein, after cleavage of the signal peptide, is heavily glycosylated and migrates as an 88 kDa protein (Karamysheva2019Granulin). 

The quaternary structure involves the assembly of granulin peptides within the lysosome, where PGRN is processed into individual granulin peptides (Zhang2022Differential). These peptides are involved in various cellular functions, including lysosomal targeting and interaction with receptor proteins like sortilin (Karamysheva2019Granulin).

## Function
The GRN gene encodes progranulin (PGRN), a multifunctional protein involved in various physiological processes. PGRN is a growth factor that plays a crucial role in inflammation regulation, wound healing, and tumorigenesis. It is expressed in a wide range of tissues, including neurons, immune cells, and epithelial cells, and functions as a modulator of cell growth and survival (Toh2011Structure; Paushter2018The). PGRN is involved in signaling pathways such as MAPK/ERK, PI3K/Akt, and FAK, which are essential for cellular proliferation and migration (Paushter2018The).

In the central nervous system, PGRN acts as a neurotrophic factor, promoting neuron survival and neurite outgrowth. It is associated with Notch receptor signaling and is crucial for maintaining lysosomal function, which is vital for cellular health and preventing neurodegeneration (Toh2011Structure; Paushter2018The). PGRN also acts as an antagonist to tumor necrosis factor-alpha (TNF-α) by binding to TNF receptors, thereby inhibiting TNF-α-mediated inflammatory responses (Tang2011The).

PGRN is processed into granulin peptides, which have distinct biological activities. While PGRN generally exhibits anti-inflammatory effects, granulin peptides are pro-inflammatory, highlighting the complex regulatory roles of PGRN and its derivatives in immune function (Toh2011Structure; Paushter2018The).

## Clinical Significance
Mutations in the GRN gene are significantly associated with several neurodegenerative diseases. One of the primary conditions linked to GRN mutations is frontotemporal lobar degeneration (FTLD), particularly the subtype with TDP-43 pathology, known as FTLD-TDP. GRN mutations account for a substantial proportion of familial FTLD cases, leading to haploinsufficiency and neurodegeneration (Rademakers2008Common; Pottier2018Potential). The rs5848 polymorphism in the GRN gene, located in a microRNA binding site, is a notable risk factor for FTLD-U, as it enhances translational inhibition of GRN, mimicking loss-of-function mutations (Rademakers2008Common).

GRN mutations are also implicated in neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disorder, where homozygous loss of GRN can cause the disease (Terryn2021Tweaking). In Alzheimer's disease, GRN levels in cerebrospinal fluid increase with disease progression, correlating with cognitive decline (Terryn2021Tweaking). GRN is further associated with Parkinson's disease, where it supports neuronal health and resilience to neurotoxicity (Terryn2021Tweaking). These findings underscore the clinical significance of GRN in various neurodegenerative and lysosomal storage disorders.

## Interactions
The GRN gene encodes the granulin precursor protein, which interacts with several proteins, influencing various cellular processes. Progranulin (PGRN), the protein product of GRN, binds to tumor necrosis factor receptors (TNFRs), specifically TNFR1 and TNFR2. This interaction is significant as PGRN can block TNF-α from binding to these receptors, providing anti-inflammatory effects. PGRN binds with higher affinity to TNFR2 compared to TNF-α, and this interaction is crucial for its role in inflammatory diseases (Wang2015New).

PGRN also interacts with prosaposin (PSAP), a lysosomal protein. This interaction is mediated by the granulin motifs in PGRN and the BC linker region in PSAP. The binding facilitates lysosomal trafficking, which is essential for maintaining proper lysosomal function (Zhou2017The).

In the context of cancer, GRN interacts with the transcription factor STAT3, enhancing its transcriptional activity. This interaction is important in breast cancer, where GRN is necessary for maximal cytokine-induced STAT3 activity, correlating with aggressive cancer phenotypes and poorer prognosis (Yeh2015Granulin).


## References


[1. (Zhang2022Differential) Tingting Zhang, Huan Du, Mariela Nunez Santos, Xiaochun Wu, Mitchell D. Pagan, Lianne Jillian Trigiani, Nozomi Nishimura, Thomas Reinheckel, and Fenghua Hu. Differential regulation of progranulin derived granulin peptides. Molecular Neurodegeneration, February 2022. URL: http://dx.doi.org/10.1186/s13024-021-00513-9, doi:10.1186/s13024-021-00513-9. This article has 13 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s13024-021-00513-9)

[2. (Karamysheva2019Granulin) Zemfira N. Karamysheva, Elena B. Tikhonova, and Andrey L. Karamyshev. Granulin in frontotemporal lobar degeneration: molecular mechanisms of the disease. Frontiers in Neuroscience, April 2019. URL: http://dx.doi.org/10.3389/fnins.2019.00395, doi:10.3389/fnins.2019.00395. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnins.2019.00395)

[3. (Pottier2018Potential) Cyril Pottier, Xiaolai Zhou, Ralph B Perkerson, Matt Baker, Gregory D Jenkins, Daniel J Serie, Roberta Ghidoni, Luisa Benussi, Giuliano Binetti, Adolfo López de Munain, Miren Zulaica, Fermin Moreno, Isabelle Le Ber, Florence Pasquier, Didier Hannequin, Raquel Sánchez-Valle, Anna Antonell, Albert Lladó, Tammee M Parsons, NiCole A Finch, Elizabeth C Finger, Carol F Lippa, Edward D Huey, Manuela Neumann, Peter Heutink, Matthis Synofzik, Carlo Wilke, Robert A Rissman, Jaroslaw Slawek, Emilia Sitek, Peter Johannsen, Jørgen E Nielsen, Yingxue Ren, Marka van Blitterswijk, Mariely DeJesus-Hernandez, Elizabeth Christopher, Melissa E Murray, Kevin F Bieniek, Bret M Evers, Camilla Ferrari, Sara Rollinson, Anna Richardson, Elio Scarpini, Giorgio G Fumagalli, Alessandro Padovani, John Hardy, Parastoo Momeni, Raffaele Ferrari, Francesca Frangipane, Raffaele Maletta, Maria Anfossi, Maura Gallo, Leonard Petrucelli, EunRan Suh, Oscar L Lopez, Tsz H Wong, Jeroen G J van Rooij, Harro Seelaar, Simon Mead, Richard J Caselli, Eric M Reiman, Marwan Noel Sabbagh, Mads Kjolby, Anders Nykjaer, Anna M Karydas, Adam L Boxer, Lea T Grinberg, Jordan Grafman, Salvatore Spina, Adrian Oblak, M-Marsel Mesulam, Sandra Weintraub, Changiz Geula, John R Hodges, Olivier Piguet, William S Brooks, David J Irwin, John Q Trojanowski, Edward B Lee, Keith A Josephs, Joseph E Parisi, Nilüfer Ertekin-Taner, David S Knopman, Benedetta Nacmias, Irene Piaceri, Silvia Bagnoli, Sandro Sorbi, Marla Gearing, Jonathan Glass, Thomas G Beach, Sandra E Black, Mario Masellis, Ekaterina Rogaeva, Jean-Paul Vonsattel, Lawrence S Honig, Julia Kofler, Amalia C Bruni, Julie Snowden, David Mann, Stuart Pickering-Brown, Janine Diehl-Schmid, Juliane Winkelmann, Daniela Galimberti, Caroline Graff, Linn Öijerstedt, Claire Troakes, Safa Al-Sarraj, Carlos Cruchaga, Nigel J Cairns, Jonathan D Rohrer, Glenda M Halliday, John B Kwok, John C van Swieten, Charles L White, Bernardino Ghetti, Jill R Murell, Ian R A Mackenzie, Ging-Yuek R Hsiung, Barbara Borroni, Giacomina Rossi, Fabrizio Tagliavini, Zbigniew K Wszolek, Ronald C Petersen, Eileen H Bigio, Murray Grossman, Vivianna M Van Deerlin, William W Seeley, Bruce L Miller, Neill R Graff-Radford, Bradley F Boeve, Dennis W Dickson, Joanna M Biernacka, and Rosa Rademakers. Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and grn mutations: a genome-wide association study. The Lancet Neurology, 17(6):548–558, June 2018. URL: http://dx.doi.org/10.1016/s1474-4422(18)30126-1, doi:10.1016/s1474-4422(18)30126-1. This article has 119 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s1474-4422(18)30126-1)

[4. (Yeh2015Granulin) Jennifer E. Yeh, Simion Kreimer, Sarah R. Walker, Megan M. Emori, Hannah Krystal, Andrea Richardson, Alexander R. Ivanov, and David A. Frank. Granulin, a novel stat3-interacting protein, enhances stat3 transcriptional function and correlates with poorer prognosis in breast cancer. Genes &amp; Cancer, 6(3–4):153–168, April 2015. URL: http://dx.doi.org/10.18632/genesandcancer.58, doi:10.18632/genesandcancer.58. This article has 22 citations.](https://doi.org/10.18632/genesandcancer.58)

[5. (Paushter2018The) Daniel H. Paushter, Huan Du, Tuancheng Feng, and Fenghua Hu. The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathologica, 136(1):1–17, May 2018. URL: http://dx.doi.org/10.1007/s00401-018-1861-8, doi:10.1007/s00401-018-1861-8. This article has 150 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00401-018-1861-8)

[6. (Rademakers2008Common) Rosa Rademakers, Jason L. Eriksen, Matt Baker, Todd Robinson, Zeshan Ahmed, Sarah J. Lincoln, Nicole Finch, Nicola J. Rutherford, Richard J. Crook, Keith A. Josephs, Bradley F. Boeve, David S. Knopman, Ronald C. Petersen, Joseph E. Parisi, Richard J. Caselli, Zbigniew K. Wszolek, Ryan J. Uitti, Howard Feldman, Michael L. Hutton, Ian R. Mackenzie, Neill R. Graff-Radford, and Dennis W. Dickson. Common variation in the mir-659 binding-site of grn is a major risk factor for tdp43-positive frontotemporal dementia. Human Molecular Genetics, 17(23):3631–3642, August 2008. URL: http://dx.doi.org/10.1093/hmg/ddn257, doi:10.1093/hmg/ddn257. This article has 239 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddn257)

[7. (Terryn2021Tweaking) Joke Terryn, Catherine M. Verfaillie, and Philip Van Damme. Tweaking progranulin expression: therapeutic avenues and opportunities. Frontiers in Molecular Neuroscience, July 2021. URL: http://dx.doi.org/10.3389/fnmol.2021.713031, doi:10.3389/fnmol.2021.713031. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnmol.2021.713031)

[8. (Zhou2017The) Xiaolai Zhou, Peter M. Sullivan, Lirong Sun, and Fenghua Hu. The interaction between progranulin and prosaposin is mediated by granulins and the linker region between saposin b and c. Journal of Neurochemistry, 143(2):236–243, August 2017. URL: http://dx.doi.org/10.1111/jnc.14110, doi:10.1111/jnc.14110. This article has 31 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/jnc.14110)

[9. (Toh2011Structure) Huishi Toh, Babykumari P. Chitramuthu, Hugh P. J. Bennett, and Andrew Bateman. Structure, function, and mechanism of progranulin; the brain and beyond. Journal of Molecular Neuroscience, 45(3):538–548, June 2011. URL: http://dx.doi.org/10.1007/s12031-011-9569-4, doi:10.1007/s12031-011-9569-4. This article has 110 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12031-011-9569-4)

[10. (Wang2015New) Betty C. Wang, Helen Liu, Ankoor Talwar, and Jinlong Jian. New discovery rarely runs smooth: an update on progranulin/tnfr interactions. Protein &amp; Cell, 6(11):792–803, September 2015. URL: http://dx.doi.org/10.1007/s13238-015-0213-x, doi:10.1007/s13238-015-0213-x. This article has 42 citations.](https://doi.org/10.1007/s13238-015-0213-x)

[11. (Tang2011The) Wei Tang, Yi Lu, Qing-Yun Tian, Yan Zhang, Feng-Jin Guo, Guang-Yi Liu, Nabeel Muzaffar Syed, Yongjie Lai, Edward Alan Lin, Li Kong, Jeffrey Su, Fangfang Yin, Ai-Hao Ding, Alexandra Zanin-Zhorov, Michael L. Dustin, Jian Tao, Joseph Craft, Zhinan Yin, Jian Q. Feng, Steven B. Abramson, Xiu-Ping Yu, and Chuan-ju Liu. The growth factor progranulin binds to tnf receptors and is therapeutic against inflammatory arthritis in mice. Science, 332(6028):478–484, April 2011. URL: http://dx.doi.org/10.1126/science.1199214, doi:10.1126/science.1199214. This article has 603 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.1199214)